Archive · 2 Jun 2025
Biocon Receives Regulatory Approval for Diabetes Drug in India
Imagine a medicine that helps people with Type 2 diabetes.
Biocon, a company, got permission to sell its version of this medicine called Liraglutide in India.
This medicine comes in a special pen that you inject.
It helps lower blood sugar and can help people lose weight.
The medicine is for adults, teenagers, and kids over 10 who have Type 2 diabetes.
It works alongside a healthy diet and exercise to keep blood sugar levels under control.
The company is now getting ready to start selling the medicine in India with the help of partners.
This will help people with diabetes.
Biocon received regulatory approval for its Liraglutide drug in India.
The drug is a generic version of Novo Nordisk’s Victoza.
It is indicated for treating Type 2 diabetes in adults, adolescents, and children aged 10 and above.
The approval was granted by the CDSCO.
Biocon will launch the product in India through commercialisation partners.
- Who
- Biocon, along with its subsidiary Biocon Pharma, received regulatory approval.
- What
- Regulatory approval for Liraglutide, a drug for Type 2 diabetes, in India.
- When
- Recently
- Where
- India
- Why
- To address the critical unmet need of diabetes management in India.
- Company
- Biocon Limited
- Drug Name
- Liraglutide
- Indication
- Type 2 diabetes
- Form
- 6 mg/ml solution for injection
- Target Demographic
- Adults, adolescents, and children aged 10 and above
- Regulatory Body
- Central Drugs Standard Control Organisation (CDSCO)